Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab

Abstract Background In malignancy, eosinophils have been shown to play an important role in the tumour micro‐environment. Increasingly, development of eosinophilia with immune checkpoint inhibitor (ICI) use is thought to be predictive of prognosis and development of immune‐related adverse events. Ho...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Gaik Tin Quah, Gillian Blanchard, Neil Miller, Paul Wilson, Ina Nordman
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2022-10-01
Reeks:	Cancer Reports
Onderwerpen:	durvalumab eosinophilia immune checkpoint inhibitors immunotherapy Strongyloides
Online toegang:	https://doi.org/10.1002/cnr2.1682
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!